News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
318,270 Results
Type
Article (26150)
Company Profile (154)
Press Release (291966)
Section
Business (91266)
Career Advice (1299)
Deals (14146)
Drug Delivery (77)
Drug Development (38238)
Employer Resources (152)
FDA (7966)
Job Trends (8528)
News (153254)
Policy (13443)
Tag
Academia (1956)
Alliances (25080)
Alzheimer's disease (778)
Approvals (7938)
Artificial intelligence (100)
Bankruptcy (92)
Best Places to Work (7284)
Biotechnology (94)
Breast cancer (99)
Cancer (723)
Cardiovascular disease (71)
Career advice (1142)
Cell therapy (174)
Clinical research (30499)
Collaboration (319)
Compensation (99)
COVID-19 (1294)
C-suite (80)
Cystic fibrosis (67)
Data (879)
Diabetes (103)
Diagnostics (3249)
Earnings (25649)
Employer resources (133)
Events (47907)
Executive appointments (277)
FDA (8401)
Funding (274)
Gene therapy (138)
GLP-1 (354)
Government (2261)
Healthcare (9785)
Infectious disease (1352)
Inflammatory bowel disease (89)
Interviews (193)
IPO (6316)
Job creations (1564)
Job search strategy (1002)
Layoffs (171)
Legal (2159)
Lung cancer (100)
Lymphoma (64)
Manufacturing (126)
Medical device (6208)
Medtech (6212)
Mergers & acquisitions (7997)
Metabolic disorders (266)
Neuroscience (992)
NextGen Class of 2024 (3655)
Non-profit (3450)
Northern California (967)
Obesity (151)
Opinion (117)
People (33009)
Phase I (8771)
Phase II (13168)
Phase III (11322)
Pipeline (270)
Postmarket research (1237)
Preclinical (3851)
Radiopharmaceuticals (115)
Rare diseases (186)
Real estate (3183)
Regulatory (9808)
Research institute (1719)
Resumes & cover letters (165)
Southern California (772)
Startups (2361)
United States (8357)
Vaccines (259)
Weight loss (105)
Date
Today (20)
Last 7 days (364)
Last 30 days (1421)
Last 365 days (20032)
2024 (19932)
2023 (22460)
2022 (27552)
2021 (30632)
2020 (28328)
2019 (25200)
2018 (18732)
2017 (16363)
2016 (15825)
2015 (17415)
2014 (12650)
2013 (10239)
2012 (10756)
2011 (11091)
2010 (10054)
Location
Africa (473)
Arizona (79)
Asia (18377)
Australia (3337)
California (2099)
Canada (684)
China (146)
Colorado (88)
Connecticut (116)
Europe (45520)
Florida (309)
Georgia (88)
Illinois (206)
Indiana (184)
Japan (71)
Maryland (300)
Massachusetts (1636)
Michigan (97)
Minnesota (154)
New Jersey (706)
New York (636)
North Carolina (475)
Northern California (967)
Ohio (93)
Pennsylvania (455)
South America (625)
Southern California (772)
Texas (270)
Washington State (149)
318,270 Results for "kezar life sciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Kezar Cuts Lupus Program After Patient Deaths, Focuses on Autoimmune Hepatitis
Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed on an FDA clinical hold. Now, that program is being terminated.
October 17, 2024
·
2 min read
·
Annalee Armstrong
FDA
Kezar’s Autoimmune Drug Hit With Second FDA Clinical Hold in as Many Months
Following patient deaths in a lupus trial that led to the termination of that program, Kezar’s autoimmune candidate zetomipzomib faces a partial clinical hold barring four trial participants from continuing treatment in the open-label portion of the trial, though the trial itself will continue as planned.
November 13, 2024
·
2 min read
·
Heather McKenzie
Biotech Bay
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
Kezar Life Sciences, Inc. (Nasdaq: KZR) today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 12:30 pm ET in New York, NY.
May 29, 2024
·
1 min read
M&A
Concentra Spies New Target After Kezar’s Lupus Trial Hold
After four patient deaths, Kezar’s lupus trial is officially on hold, sparking investor Kevin Tang’s interest for acquisition.
October 9, 2024
·
1 min read
·
Kate Goodwin
Press Releases
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
October 28, 2024
·
2 min read
Press Releases
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
·
9 min read
Immunology and inflammation
Kezar Reports Four Patient Deaths in Mid-Stage Lupus Nephritis Study, Pauses Enrollment
William Blair analyst Matt Phipps in a note to investors wrote that despite the patient deaths, the totality of the data still leans in favor of Kezar Life Sciences’ investigational immunoproteasome inhibitor zetomipzomib.
October 1, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
October 7, 2024
·
3 min read
Business
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
Kezar Life Sciences, Inc., a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, reported financial results for the first quarter ended March 31, 2024 and provided a business update.
May 9, 2024
·
8 min read
Drug Development
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
October 17, 2024
·
5 min read
1 of 31,827
Next
